Table 2 First-line treatment patterns for the included patients with extensive-stage small cell lung cancer (ES-SCLC)
Treatment received | n/N (%) | |
|---|---|---|
Chemotherapy alone | Carboplatin + etoposide | 114/548 (20.8) |
Cisplatin + etoposide | 9/548 (1.6) | |
Chemoimmunotherapy | Atezolizumab + carboplatin + etoposide | 252/548 (46.0) |
Durvalumab + carboplatin + etoposide | 122/548 (22.3) | |
Durvalumab + cisplatin + etoposide | 35/548 (6.4) | |
Other | 16/548 (2.9) | |
Number of administered chemotherapy cycles | 1 | 35/530 (6.6) |
2 | 25/530 (4.7) | |
3 | 25/530 (4.7) | |
4 | 284/530 (53.6) | |
5 | 21/530 (4.0) | |
6 | 124/530 (23.4) | |
> 7 | 16/530 (3.0) | |
Receipt of maintenance immunotherapy | 340/548 (62.0) | |
Receipt of radiotherapy | None | 365/539 (67.9) |
Brain radiotherapy alone | 103/539 (19.1) | |
Thoracic radiotherapy | 34/539 (6.3) | |
Brain radiotherapy + thoracic radiotherapy | 18/539 (3.3) | |
Prophylactic cranial irradiation | 18/539 (3.3) | |